Â鶹´«Ã½Ó³»­

Â鶹´«Ã½Ó³»­

Explore the latest content from across our publications
Join The Â鶹´«Ã½Ó³»­

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Real-world outcomes with ocrelizumab compared with other disease-modifying therapies in US commercial claims databases
Multiple Sclerosis
P9 - Poster Session 9 (12:00 PM-1:00 PM)
9-010
To describe patient characteristics and differences in annualized relapse rates (ARRs) 1-year post-initiation of ocrelizumab vs other multiple sclerosis (MS) disease-modifying therapies (DMTs) in a real-world setting. 
Ocrelizumab demonstrated efficacy in Phase III trials in relapsing (OPERA I, OPERA II) and primary progressive (ORATORIO) forms of MS. Evidence of real-world effectiveness of ocrelizumab is limited.
This analysis used the PharMetrics Plus national claims database of 140+ million enrollees. Patients with MS who initiated a new DMT in April 1, 2017–March 31, 2018 and were enrolled for ≥1 year pre- and post-initiation of the new DMT (index date) were included. Patients were not required to be treatment naive prior to the index date. Comparator DMTs were grouped by administration route: injectable (interferon β-1a/b, glatiramer acetate, peginterferon β-1a), oral (dimethyl fumarate, fingolimod, teriflunomide) and intravenous (natalizumab). Patient characteristics on the index date are described; unadjusted ARRs (validated claims-based relapse algorithm) are reported by quarter for pre- and post-initiation years. Adjusted differences evaluated using Poisson regression will be available for presentation.
This study included 2,713 patients (ocrelizumab, n=729; injectables, n=662; orals, n=1,109; natalizumab, n=213). Compared with patients treated with other DMTs, ocrelizumab-treated patients were older (mean [SD] age, 49 [10] years) and less likely to be female (63% vs ≥70% with other DMTs). Natalizumab had the highest pre-initiation ARR (0.60), followed by ocrelizumab (0.54), injectables (0.33) and orals (0.33). ARRs increased noticeably in the quarter prior to initiation of injectables (0.85), orals (0.75) and natalizumab (1.1); for ocrelizumab, ARRs were similar in the quarter prior to switch (0.60). Ocrelizumab had the greatest ARR reduction (Δ=–0.31) from pre-initiation to post-initiation year, followed by natalizumab (Δ=–0.19), orals (Δ=–0.12) and injectables (Δ=–0.08).
Preliminary results suggest a greater reduction in relapses post-initiation with ocrelizumab vs available DMTs.
Authors/Disclosures
Natalie J. Engmann, PhD (Genentech, Inc)
PRESENTER 		No disclosure on file
Daniel Sheinson No disclosure on file
No disclosure on file
Damian Fiore Damian Fiore has nothing to disclose.
Enrique Alvarez, MD, PhD (University of Colorado) Dr. Alvarez has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for TG Therapeutics. Dr. Alvarez has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biogen. Dr. Alvarez has received personal compensation in the range of $50,000-$99,999 for serving on a Scientific Advisory or Data Safety Monitoring board for EMD Serono. Dr. Alvarez has received personal compensation in the range of $50,000-$99,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Genentech. Dr. Alvarez has received personal compensation in the range of $50,000-$99,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis. Dr. Alvarez has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche. Dr. Alvarez has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Sanofi. Dr. Alvarez has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Celgene/BMS. The institution of an immediate family member of Dr. Alvarez has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for UCB. The institution of Dr. Alvarez has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Horizon.
Kavita Nair, PhD, FÂ鶹´«Ã½Ó³»­ (University of Colorado) Dr. Nair has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Bristol Meyers Squibb. Dr. Nair has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Novartis. Dr. Nair has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for PhRMA Foundation. Dr. Nair has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Genentech. Dr. Nair has received personal compensation in the range of $500-$4,999 for serving as a Consultant for TG Therapeutics. Dr. Nair has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for MJH Lifesciences. Dr. Nair has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Sanofi. Dr. Nair has received personal compensation in the range of $500-$4,999 for serving as a Consultant for EMD Serono. Dr. Nair has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Amgen. Dr. Nair has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Anylam . Dr. Nair has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Applied Patient Experience. Dr. Nair has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Esai. Dr. Nair has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for MHJ Life Sciences. Dr. Nair has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Sanofi-Genzyme. Dr. Nair has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Amgen. Dr. Nair has received personal compensation in the range of $500-$4,999 for serving as an officer or member of the Board of Directors for ICER. The institution of Dr. Nair has received research support from Genentech. The institution of Dr. Nair has received research support from Novartis. The institution of Dr. Nair has received research support from Genentech. The institution of Dr. Nair has received research support from Phrma Foundation. The institution of Dr. Nair has received research support from Bristol Meyers Squibb. The institution of Dr. Nair has received research support from Novartis. The institution of Dr. Nair has received research support from NINDS. The institution of Dr. Nair has received research support from Sanofi Genzyme. The institution of Dr. Nair has received research support from Kyverna Therapeutcis. Dr. Nair has a non-compensated relationship as a Board Member with Center for Improving Value in Healthcare that is relevant to Â鶹´«Ã½Ó³»­ interests or activities.
Timothy L. Vollmer, MD, FÂ鶹´«Ã½Ó³»­ The institution of Dr. Vollmer has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Biogen IDEC. The institution of Dr. Vollmer has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Genentech/Roche. The institution of Dr. Vollmer has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Siranax. The institution of Dr. Vollmer has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Celgene. The institution of Dr. Vollmer has received personal compensation in the range of $500-$4,999 for serving as a Consultant for EMD Serono. The institution of Dr. Vollmer has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Bristol Meyers Squib. The institution of Dr. Vollmer has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Viela Bios. The institution of Dr. Vollmer has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Novartis. The institution of Dr. Vollmer has received research support from Rocky Mountain MS Center. The institution of Dr. Vollmer has received research support from Biogen. The institution of Dr. Vollmer has received research support from Actelion. The institution of Dr. Vollmer has received research support from Genentech/Roche. The institution of Dr. Vollmer has received research support from Anokion. The institution of Dr. Vollmer has received research support from TG Therapeutics.